Giacobello Scott M. 4

What Happened

• Scott M. Giacobello, Chief Financial Officer of Whitehawk Therapeutics (WHWK), sold a total of 218,600 shares in two broker-assisted transactions: 77,000 shares on 2026-04-15 at $3.86 ($297,220) and 141,600 shares on 2026-04-16 at $4.13 ($584,808). Total proceeds were $882,028. These sales were reported on a Form 4 filed 2026-04-17.
• These were sales (not purchases). The filing identifies the transactions as broker-assisted sales to satisfy tax withholding obligations tied to RSU vesting (footnote F1), which is a routine tax-related sale rather than an open-market investment decision.

Key Details

• Transaction dates/prices: 2026-04-15 — 77,000 shares @ $3.86 ($297,220); 2026-04-16 — 141,600 shares @ $4.13 ($584,808).
• Total shares sold: 218,600; total proceeds: $882,028.
• Filing date: Form 4 filed 2026-04-17 for transactions on 2026-04-15 and 2026-04-16 — appears timely under Form 4 rules.
• Shares owned after the transactions: not specified in the filing.
• Footnotes: F1 = broker-assisted sale to satisfy tax withholding for RSU vesting; F2 notes an aggregate 11,822 shares were acquired under the Issuer’s 2021 Employee Stock Purchase Plan between 11/14/2022 and 11/15/2025.
• Transaction code: S = Sale (tax-withholding sale noted in footnote).

Context

• Broker-assisted sales to cover tax withholding for vested restricted stock units are common and typically routine; they do not necessarily signal a change in the insider’s view of the company.
• For retail investors, purchases by insiders tend to be more informative as bullish signals; routine tax-withholding sales are less indicative of company outlook.